Piramal Pharma Limited has informed the Exchange about Transcript

Investor Communications View source PDF Explain this filing

PPLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.1%Reaction day

₹201.19

prior close

₹199.21

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.9%-1.2% vs market

Pharmaceuticals peers, median of 151sector-0.8%-1.2% vs sector

On the reaction day the stock moved 1.2 pts less than Nifty Smallcap 250 and 1.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.1-0.9-1.2-0.8-1.2

Next day

-5.3-2.5-2.8-2.8-2.5

-3.0-1.6-1.4-2.2-0.8

-3.8-1.9-1.9-2.9-1.0

-7.3-3.1-4.2-4.7-2.6

-4.2-3.2-1.1-4.1-0.2

-5.6-4.0-1.7-4.2-1.4

15d

-4.2-1.4-2.8-3.6-0.6

-6.5-3.3-3.2-4.7-1.8

-5.0-3.5-1.5-7.1+2.1

-0.2+0.1-0.3-6.1+6.0

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 151Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Piramal Pharma has submitted to the stock exchanges the transcript of its conference call held on 29th July 2025, discussing the unaudited standalone and consolidated financial results for the quarter ended 30th June 2025. The transcript is now available on the company's website. No specific financial figures, guidance, or strategic commentary are disclosed in this filing — it is a routine regulatory submission under SEBI Listing Regulations. Investors can review the full transcript on the company's investor relations page for management's detailed commentary on Q1 performance.

Likely market impact

No direct impact on the stock price from this filing alone, as it is a procedural disclosure. Investors seeking management commentary on margins, growth outlook, or strategy should review the actual conference call transcript on the company's website.